RFB002, rhuFab V2 ( DrugBank: rhuFab V2 )


1 disease
IDDisease name (Link within this page)Number of trials
166Pseudoxanthoma elasticum1

166. Pseudoxanthoma elasticum


Clinical trials : 15 Drugs : 27 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 28
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-006231-49-DE
(EUCTR)
24/07/200706/03/2007Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06 Pseudoxanthoma elasticum (PXE) is an inherited systemic disease characterized by changes in the elastic tissue. Pseudoxanthoma elasticum mainly affects the skin, eyes, heart, and GI system. The cutaneous and ocular findings of PXE are referred to as Grönblad-Strandberg syndrome. Pseudoxanthoma elasticum may be autosomal dominant or autosomal recessive. In Pseudoxanthoma elasticum, choroidal nevoscualrization (CNV) is a frequently occuring complication in late stage disease
MedDRA version: 8.1;Level: LLT;Classification code 10037150;Term: Pseudoxanthoma elasticum
Trade Name: Lucentis
Product Name: Lucentis
Product Code: RFB002
INN or Proposed INN: ranibizumab
Other descriptive name: RFB002, rhuFab V2
Department of Ophthalmology, Bonn UniversityNULLNot RecruitingFemale: yes
Male: yes
10Phase 2Germany